Our results support that inhibiting TACR1 with the antagonist, fosaprepitant, provides a therapeutic effect in a mouse model of neuroblastoma, and present fosaprepitant as a possible clinical avenue for patients with neuroblastomas with high-level TACR1 expression. This evidence concerns the gene TACR1 and neuroblastoma.